ClinicalTrials.Veeva

Menu

Phase 2b Study of ALTO-100 in MDD

Alto Neuroscience logo

Alto Neuroscience

Status and phase

Active, not recruiting
Phase 2

Conditions

Major Depressive Disorder

Treatments

Drug: ALTO-100
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT05712187
ALTO-100-201

Details and patient eligibility

About

The purpose of this study is to determine efficacy differences between ALTO-100 and placebo, used either as monotherapy or adjunctively to an antidepressant, related to patient characteristics.

Enrollment

301 patients

Sex

All

Ages

18 to 64 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Have a diagnosis of moderate to severe major depressive disorder (MDD)
  • At baseline, either not taking an antidepressant medication, or currently taking a single SSRI, SNRI, mirtazapine, or bupropion for at least 6 weeks with no dose modifications in the past 2 weeks
  • Willing to comply with all study assessments and procedures
  • Must not be pregnant or breastfeeding at time of enrollment or throughout study

Exclusion criteria

  • Evidence of unstable medical condition
  • Diagnosed bipolar disorder, psychotic disorder, or dementia
  • Current moderate or severe substance use disorder
  • Has a history of hypersensitivity or allergic reaction to ALTO-100 or any of its components/excipients
  • Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

301 participants in 2 patient groups, including a placebo group

ALTO-100
Experimental group
Description:
Participants will receive ALTO-100 tablet twice daily, from Day 1 to Day 42 in double blind (DB) treatment period. Eligible participants who will enter the open label (OL) treatment period will receive ALTO-100 tablet twice daily from OL baseline until the end of OL period/early termination visit (Up to 7 weeks).
Treatment:
Drug: ALTO-100
Placebo DB
Placebo Comparator group
Description:
Participants will receive matching placebo tablet twice daily, from Day 1 to Day 42 in double blind (DB) treatment period.
Treatment:
Drug: Placebo

Trial contacts and locations

35

Loading...

Central trial contact

Alto Neuroscience

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems